Share on StockTwits

Consort Medical plc (LON:CSRT) has earned an average recommendation of “Hold” from the nine brokerages that are covering the stock, AmericanBankingNews.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is GBX 959.86 ($16.17).

Consort Medical plc (LON:CSRT) traded up 1.45% during mid-day trading on Tuesday, hitting GBX 908.00. The stock had a trading volume of 495 shares. Consort Medical plc has a one year low of GBX 733.00 and a one year high of GBX 1113.00. The stock has a 50-day moving average of GBX 919.2 and a 200-day moving average of GBX 945.4. The company’s market cap is £261.2 million.

A number of research firms have recently commented on CSRT. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Consort Medical plc in a research note on Tuesday. They now have a GBX 1,044 ($17.58) price target on the stock. Separately, analysts at FinnCap reiterated a “sell” rating on shares of Consort Medical plc in a research note on Tuesday. They now have a GBX 690 ($11.62) price target on the stock. Finally, analysts at Nplus1 Brewin reiterated a “hold” rating on shares of Consort Medical plc in a research note on Wednesday, March 19th. They now have a GBX 1,020 ($17.18) price target on the stock.

Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.